Following a second measles-related death in Texas, Robert F. | The HHS secretary called out the measles vaccines as "the most ...

ABL Bio Inc. sealed a potential £2.075 billion (US$2.65 billion) license deal with GSK plc, granting GSK global rights to use ABL’s blood-brain barrier penetrating bispecific antibody platform, ...

The pharma giant is wagering potentially billions of dollars on technology from ABL Bio that’s designed to get drugs across ...

GSK pays ABL Bio $49.5M upfront for blood-brain barrier platform access, with potential $2.67B in milestone payments. Deal ...

GSK is paying to access ABL Bio’s Grabody-B platform, which potentially enables therapies to cross the blood-brain barrier.

Duality Biologics has begun (PDF) offering stock, wading into a market reeling from Presid | Duality Biologics has begun ...

NEW YORK CITY, NY / ACCESS Newswire / April 7, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

GSK has continued to flesh out its neuroscience strategy with a 2 billion pound sterling ($2.5 billion) deal to use a South ...

ABL Bio has announced a global licensing agreement with GSK, allowing the latter to develop medicines for neurodegenerative ...

NEW YORK CITY, NY / ACCESS Newswire / April 6, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

GSK and Pfiz­er have set­tled a law­suit al­leg­ing Pfiz­er’s RSV shot Abrys­vo in­fringed GSK’s patents. A Pfiz­er ...

GSK Plc and Pfizer Inc. settled a patent-infringement lawsuit over competing vaccines for RSV, ending the dispute in Delaware ...